Fig. 3From: Real-world evidence on the strategy of olmesartan-based triple single-pill combination in Korean hypertensive patients: a prospective, multicenter, observational study (RESOLVE-PRO)Time course change from baseline in the mean SBP/DBP at month 3, 6, 9, and 12 after olmesartan/amlodipine/hydrochlorothiazide (OM/AML/HCTZ) administration. Effectiveness set (n = 3052). BP, blood pressure; SBP, systolic BP; DBP, diastolic BPBack to article page